Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against iRobot Corporation for alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by September 5, 2025 [3][5]. Group 1: Allegations Against iRobot - The complaint alleges that iRobot and its executives made false and misleading statements regarding the effectiveness of the Restructuring Plan following the termination of the Amazon Acquisition [5]. - It is claimed that iRobot overstated its ability to operate profitably as a standalone company, raising substantial doubt about its ability to continue as a going concern [5]. - The company's public statements were deemed materially false and misleading at all relevant times [5]. Group 2: Financial Performance - iRobot reported a loss of $2.06 per share on revenue of $172 million for Q4 and full year 2024, marking a 44% year-over-year decline [6]. - The company expressed uncertainty regarding the success of new product launches due to various factors, including consumer demand and macroeconomic conditions, indicating substantial doubt about its financial viability for at least 12 months [6]. Group 3: Market Reaction - Following the announcement of its financial results, iRobot's stock price fell by $3.255 per share, or 51.58%, closing at $3.055 per share on March 13, 2025 [7].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Rocket Pharmaceuticals due to significant losses suffered by investors following misleading statements regarding the safety of its clinical trial for RP-A501 [2][4]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi, LLP is encouraging investors who incurred losses exceeding $50,000 in Rocket Pharmaceuticals between February 27, 2025, and May 26, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Rocket Pharmaceuticals, with a deadline of August 11, 2025, for investors to seek the role of lead plaintiff [2]. - The firm has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [3]. Group 2: Allegations Against Rocket Pharmaceuticals - The complaint alleges that Rocket Pharmaceuticals provided overly positive statements while concealing material adverse facts about the safety of RP-A501 and the clinical trial protocol [4]. - It was revealed that Rocket amended the trial protocol to include a new immunomodulatory agent without informing shareholders, which misled investors into purchasing securities at inflated prices [4]. - On May 27, 2025, the FDA placed a clinical hold on the RP-A501 Phase 2 pivotal study after a patient suffered a Serious Adverse Event, including death, which was not disclosed to investors prior to the incident [5]. Group 3: Stock Price Impact - Following the announcement of the clinical hold, Rocket's stock price plummeted from $6.27 per share on May 23, 2025, to $2.33 per share on May 27, 2025, marking a decline of approximately 37% in just one trading day [6].

Core Viewpoint - A securities class action lawsuit has been filed against Hims & Hers Health, Inc. for alleged misleading statements and failure to disclose critical information during the Class Period from April 29, 2025, to June 23, 2025 [1][2]. Company Summary - Hims & Hers is a telehealth company that offers prescription medications, over-the-counter medications, and personal care products [2]. - The company announced a collaboration with Novo Nordisk A/S on April 29, 2025, which included the sale of Novo Nordisk's FDA-approved Wegovy® on its platform [2]. - The lawsuit claims that Hims & Hers engaged in deceptive practices by promoting and selling illegitimate versions of Wegovy®, jeopardizing patient safety [5]. Legal Allegations - The lawsuit alleges that Hims & Hers made false and/or misleading statements and failed to disclose the risks associated with its collaboration with Novo Nordisk [2][5]. - On June 23, 2025, Novo Nordisk announced the termination of its partnership with Hims & Hers due to these deceptive practices, leading to a significant drop in Hims & Hers' stock price by $18.26 per share, a decline of over 34%, closing at $45.00 per share [2]. Important Dates - The lead plaintiff motion deadline for investors is August 25, 2025 [3].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Rocket Pharmaceuticals due to misleading statements regarding the safety of its clinical trial for RP-A501, which led to significant investor losses [3][5][6]. Group 1: Legal Investigation and Claims - Faruqi & Faruqi is encouraging investors who suffered losses exceeding $50,000 in Rocket Pharmaceuticals between February 27, 2025, and May 26, 2025, to discuss their legal options [1]. - The firm reminds investors of the August 11, 2025, deadline to seek the role of lead plaintiff in a federal securities class action against Rocket Pharmaceuticals [3]. - The complaint alleges that Rocket Pharmaceuticals provided positive statements while concealing material adverse facts about the safety of RP-A501 and the clinical trial protocol [5]. Group 2: Clinical Trial Issues - Rocket Pharmaceuticals faced a clinical hold from the FDA on the RP-A501 Phase 2 pivotal study after a patient suffered a Serious Adverse Event (SAE), which ultimately resulted in death [6]. - The company amended the trial protocol to introduce a new immunomodulatory agent without disclosing this critical update to investors, which is a key point of contention in the lawsuit [5][6]. Group 3: Stock Price Impact - Following the announcement of the clinical hold, Rocket's stock price plummeted from $6.27 per share on May 23, 2025, to $2.33 per share on May 27, 2025, marking a decline of approximately 37% in just one trading day [8].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against PepGen Inc. due to alleged violations of federal securities laws, encouraging affected investors to seek legal counsel before the August 11, 2025 deadline for lead plaintiff applications in a federal class action lawsuit [3][5]. Group 1: Allegations Against PepGen - The complaint alleges that PepGen and its executives made false or misleading statements regarding the effectiveness and safety of PGN-EDO51, and failed to disclose deficiencies in the CONNECT2 study, leading to overstated clinical and commercial prospects [5]. - The FDA issued a clinical hold notice for the CONNECT2 study, indicating concerns about patient risks and deficiencies in the study [8]. Group 2: Stock Price Reactions - Following the announcement of disappointing clinical data from the CONNECT1 study, PepGen's stock price fell by $5.55, or 32.69%, closing at $11.43 on July 31, 2024 [7]. - After the FDA's clinical hold notice on December 16, 2024, PepGen's stock dropped by $0.17, or 3.63%, to close at $4.51 [9]. - On January 30, 2025, PepGen's stock fell by $0.40, or 21.74%, to close at $1.44 after updates on safety concerns in the CONNECT1 study [10]. - The stock price further declined by $0.53, or 18.86%, to close at $2.28 on March 4, 2025, following the announcement to pause the CONNECT2 study [11]. - On May 28, 2025, PepGen announced the discontinuation of its DMD programs after PGN-EDO51 failed to achieve target dystrophin levels [12]. Group 3: Legal and Investor Actions - Investors who suffered losses exceeding $50,000 in PepGen between March 7, 2024, and March 3, 2025, are encouraged to contact Faruqi & Faruqi for legal options [1]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding PepGen's conduct [14].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Sarepta Therapeutics, Inc. due to allegations of violations of federal securities laws related to misleading statements about the safety of its product ELEVIDYS [2][4]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses in Sarepta between June 22, 2023, and June 24, 2025, to discuss their legal rights [1]. - There is a deadline of August 25, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against Sarepta [2]. - The complaint alleges that Sarepta and its executives made false statements regarding the safety of ELEVIDYS, which posed significant risks to patients [4]. Group 2: Stock Price Impact - Following a safety update on March 18, 2025, where a patient died after treatment with ELEVIDYS, Sarepta's stock price fell by $27.81, or 27.44%, closing at $73.54 [5]. - On April 4, 2025, after the company disclosed that EU authorities requested a review of the death, the stock price dropped by $4.18, or 7.13%, closing at $54.43 [6]. - A second patient death was reported on June 15, 2025, leading to a significant stock price decline of $15.24, or 42.12%, closing at $20.91 [7][8]. - Following an FDA Safety Communication on June 24, 2025, regarding the investigation of acute liver failure risks, the stock price fell by $1.52, or 8.01%, closing at $17.46 [8][9]. Group 3: Company Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against 3D Systems Corporation for alleged violations of federal securities laws, urging affected investors to contact them before the August 12, 2025 deadline for lead plaintiff applications in a federal class action lawsuit [2][4]. Financial Performance - 3D Systems reported Q4 2024 non-GAAP earnings-per-share of -$0.19, missing consensus estimates by $0.08, with sales revenue of $111 million, a year-over-year decline of 3.4%, and a full-year 2024 sales total of $440.1 million, down 10% from the previous year [5]. - In Q1 2025, the company reported revenue of $94.5 million, an 8% year-over-year decline, and a net loss of $37 million, or $0.28 per share, which is more than double the $16 million loss reported in Q1 2024 [6]. Stock Price Reaction - Following the Q4 2024 results announcement, 3D Systems' stock price fell by $0.57, or 20.96%, closing at $2.15 per share [5]. - After the Q1 2025 results were released, the stock price dropped by $0.68, or 26.6%, to close at $1.87 per share [7]. Allegations of Misconduct - The complaint against 3D Systems alleges that the company and its executives made false or misleading statements regarding the impact of weakened customer spending and overstated the company's resilience in challenging market conditions [4]. - It is also claimed that updated milestone criteria in the United Partnership would negatively affect the revenue from the Regenerative Medicine Program, leading to materially false public statements [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Rocket Pharmaceuticals due to misleading statements regarding the safety of its clinical trial for RP-A501, which led to significant investor losses following a serious adverse event [2][4][5]. Group 1: Company Overview - Rocket Pharmaceuticals, Inc. is a publicly traded company on NASDAQ under the ticker RCKT [2]. - The company has faced legal scrutiny following a clinical hold placed by the FDA on its RP-A501 Phase 2 pivotal study due to serious adverse events, including a participant's death [5]. Group 2: Legal Proceedings - A federal securities class action has been filed against Rocket Pharmaceuticals, with a deadline of August 11, 2025, for investors to seek the role of lead plaintiff [2][7]. - The complaint alleges that Rocket provided overly positive statements while concealing material adverse facts about the safety of RP-A501 and the clinical trial protocol [4]. Group 3: Financial Impact - Following the announcement of the FDA's clinical hold, Rocket's stock price plummeted from $6.27 per share on May 23, 2025, to $2.33 per share on May 27, 2025, marking a decline of approximately 37% in just one trading day [6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against PepGen Inc. due to allegations of misleading statements regarding the effectiveness and safety of its drug PGN-EDO51, which has led to significant stock price declines and a federal securities class action [2][4]. Group 1: Allegations and Legal Actions - The complaint against PepGen alleges violations of federal securities laws, including false statements about the effectiveness and safety of PGN-EDO51 and deficiencies in the CONNECT2 study [4]. - Investors who purchased PepGen securities between March 7, 2024, and March 3, 2025, are encouraged to discuss their legal rights and options with Faruqi & Faruqi [1][2]. - The deadline to seek the role of lead plaintiff in the federal securities class action against PepGen is August 11, 2025 [2]. Group 2: Clinical Study Results and Stock Performance - On July 30, 2024, PepGen reported "positive clinical data" from the CONNECT1 study, but analysts noted that the results were below expectations, leading to a 32.69% drop in stock price [5][6]. - Following a clinical hold notice from the FDA on December 16, 2024, due to safety concerns, PepGen's stock fell by 3.63% [7][8]. - A subsequent update on January 29, 2025, regarding safety concerns in the CONNECT1 study led to a further 21.74% decline in stock price [9][10]. - On March 4, 2025, PepGen announced a voluntary pause of the CONNECT2 study, resulting in an 18.86% drop in stock price [10]. - On May 28, 2025, PepGen disclosed that PGN-EDO51 did not achieve target dystrophin levels and decided to discontinue its DMD programs [11].

Core Points - Holzer & Holzer, LLC is investigating Quantum Corporation for potential compliance issues with federal securities laws following the company's inability to file its Annual Report on Form 10-K for the fiscal year ended March 31, 2025 [1] - Quantum disclosed that it is reviewing its accounting related to certain revenue contracts and the application of standalone selling price under applicable accounting standards, which led to a drop in its stock price [1] Company Information - Quantum Corporation trades on NASDAQ under the ticker QMCO [1] - The company has faced scrutiny due to its accounting practices, which may impact investor confidence and stock performance [1] Legal Context - Holzer & Holzer, LLC is a law firm specializing in securities litigation, representing shareholders and investors in cases of corporate misconduct [3] - The firm has a history of recovering significant amounts for shareholders affected by fraud, indicating a proactive approach to investor rights [3]